Biopharma News

Spark Therapeutics and Selecta entered a license agreement for Selecta’s gene-therapy co-administration technology.

At the American Society of Hematology Annual Meeting, Novartis and Kite Pharma both released results from early-phase clinical trials with CAR-T therapies.

Takeda and Lightstone have launched Cerevance, a neuroscience company focused on developing therapeutics for neurological and psychiatric disorders.

JHL Biotech and Sanofi collaborate on the development and commercialization of biological therapeutics in China.

Boehringer Ingelheim and China Southeast University announced a joint research collaboration to develop new regenerative treatments for hearing loss.

Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

The company plans to expand access to its Prevanar 13 vaccine in humanitarian emergency settings.

Roche launched imCORE, a global network of cancer immunotherapy centers of excellence.

The agreement allows Bristol-Myers Squibb exclusive license to manufacture and commercialize Nitto Denko Corporation’s NASH treatment.

British artificial intelligence company BenevolentAI has signed an exclusive license for a series of novel clinical-stage drug candidates with Johnson & Johnson.

The study in 48 healthy adults will assess the safety and immunogenicity of a prime-boost regime of two different intranasal doses of the RSV vaccine, SynGem.

German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.

CFDA granted Pfizer China approval for the company’s Prevenar 13 vaccine.

Astellas will acquire Ganymed and its portfolio of ideal monoclonal antibody candidates.

Bellicum and Ospedale Pediatrico Bambino Gesù will collaborate on preclinical and clinical development of CAR-T and TCR therapeutics.

Oxford Genetics has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies.

Teva and IBM expanded their partnership to focus on drug development and chronic disease management.

The collaboration follows the signing of a cooperative research agreement between Sanofi Pasteur, Fiocruz, and WRAIR.

Caribou and JAX entered into a license agreement for Caribou’s CRISPR-Cas9 gene editing technology.

Heat Biologics will collaborate with the University of Miami on the development of a Zika vaccine using the company’s gp96 platform.

Oxford Genetics increased its laboratory space to 5700 sq. ft. with a move to a new location at Oxford Science Park.

The company announced plans to begin shipping Inflectra to the US market in late November 2016.

The companies will collaborate the manufacture of personalized cancer vaccines.

Marken announced the opening of a new depot and logistics operations center in Argentina.

The companies entered into a collaboration and license agreement for Crescendo’s Humabody-based therapeutics.

WuXi AppTec’s new biomanufacturing facility is its third facility in the Philadelphia, PA Navy Yard.

Results from the Phase III POLLUX trial with Janssen’s Darzalex showed that the drug was effective at reducing disease progression in patients with relapsed or refractory multiple myeloma.

The companies are collaborating on the commercialization of two biosimilar candidates in the US and Canada.

Xellia added laboratory space and personnel in Zagreb, Croatia to work on anti-infective products that combat the antimicrobial resistance problem.

A PESU membrane is now available for Sartorius Stedim Biotech Sartocon benchtop and production-scale filtration assemblies.